Bayer (BAYN) Earns “Buy” Rating from Citigroup

Bayer (FRA:BAYN)‘s stock had its “buy” rating reaffirmed by analysts at Citigroup in a report issued on Thursday.

BAYN has been the subject of several other reports. S&P Global set a €126.00 ($150.00) price objective on shares of Bayer and gave the company a “buy” rating in a research note on Thursday, October 26th. Sanford C. Bernstein set a €131.00 ($155.95) price objective on shares of Bayer and gave the company a “buy” rating in a research note on Wednesday, November 29th. DZ Bank restated a “buy” rating on shares of Bayer in a research note on Monday, December 11th. equinet set a €118.00 ($140.48) price objective on shares of Bayer and gave the company a “buy” rating in a research note on Friday, October 13th. Finally, BNP Paribas set a €130.00 ($154.76) price objective on shares of Bayer and gave the company a “buy” rating in a research note on Monday, September 25th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and fourteen have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of €122.33 ($145.63).

Shares of Bayer (FRA BAYN) opened at €105.60 ($125.71) on Thursday. Bayer has a 12 month low of €99.69 ($118.68) and a 12 month high of €123.82 ($147.40). The company has a market cap of $87,620.00 and a P/E ratio of 28.31.

ILLEGAL ACTIVITY WARNING: “Bayer (BAYN) Earns “Buy” Rating from Citigroup” was first published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this story on another publication, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be viewed at https://www.com-unik.info/2018/01/11/bayer-bayn-earns-buy-rating-from-citigroup.html.

Bayer Company Profile

Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, Crop Science, Animal Health, and Covestro segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

Analyst Recommendations for Bayer (FRA:BAYN)

What are top analysts saying about Bayer? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Bayer and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit